Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 10:12:649807.
doi: 10.3389/fphar.2021.649807. eCollection 2021.

Purines in Pain as a Gliopathy

Giulia Magni  1 , Stefania Ceruti  1
Affiliations

Purines in Pain as a Gliopathy

Giulia Magni et al. Front Pharmacol. .
No abstract available

Keywords: A3 adenosine receptors; P2X4 receptors; P2Y12 receptors; astrocytes; microglia; satellite glial cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Schematic representation of the most promising purinergic targets for the development of new analgesics expressed by glial cells in the central nervous system (CNS), in dorsal root ganglia/trigeminal ganglia (DRG/TG) and by peripheral cells. These nucleotide (i.e., the P2Y12 and P2X4 subtypes) and adenosine (i.e., the A3 subtype) receptors are involved in the modulation of neuronal firing in chronic pain conditions. Receptor antagonists are likely to represent the best analgesic option targeting P2Y12 and P2X4 subtypes. Conversely, selective A3 receptor agonists have proved effective in reducing pain in several preclinical models. See text for details. Created with BioRender.com.
See this image and copyright information in PMC

References

    1. Agostinho P., Madeira D., Dias L., Simões A. P., Cunha R. A., Canas P. M. (2020). Purinergic signaling orchestrating neuron-glia communication. Pharmacol. Res. 162, 105253. 10.1016/j.phrs.2020.105253 - DOI - PubMed
    1. Badimon A., Strasburger H. J., Ayata P., Chen X., Nair A., Ikegami A., et al. (2020). Negative feedback control of neuronal activity by microglia. Nature 586 (7829), 417–423. 10.1038/s41586-020-2777-8 - DOI - PMC - PubMed
    1. Borea P. A., Gessi S., Merighi S., Vincenzi F., Varani K. (2018). Pharmacology of adenosine receptors: the state of the art. Physiol. Rev. 98 (3), 1591–1625. 10.1152/physrev.00049.2017 - DOI - PubMed
    1. Burnstock G. (2017). Purinergic signalling: therapeutic developments. Front. Pharmacol. 8, 661. 10.3389/fphar.2017.00661 - DOI - PMC - PubMed
    1. Chen J. F., Cunha R. (2020). The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson's disease. Purinergic Signal. 16 (2), 167–174. 10.1007/s11302-020-09694-2 - DOI - PMC - PubMed